Development of bispecific nanobody-derived CARs targeting b-cell leukemia markers: CD19, CD20, and CD22

Key Points

• To develop bispecific nanobody-derived CARs targeting B-cell leukemia markers CD19, CD20, and CD22.
• Development of bispecific nanobody-derived CARs
• Targeting specific leukemia markers
• Presentation at an international symposium
• New CAR designs implemented for CD19, CD20, and CD22
• Potential improvements in targeting B-cell leukemia
• Presented findings at a significant immunobiological event

Abstract